Moleculin Biotech Enters New Stock Offering Agreement

The latest update is out from Moleculin Biotech ( (MBRX) ).

On July 11, 2025, Moleculin Biotech, Inc. entered into an At The Market Offering Agreement with Roth Capital Partners, allowing the company to sell up to $6,500,000 of its common stock. The proceeds from these sales are intended for working capital and general corporate purposes. This agreement provides Moleculin with flexibility to raise capital as needed, depending on market conditions and the company’s financial requirements, potentially impacting its operational capabilities and market positioning.

The most recent analyst rating on (MBRX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.

Spark’s Take on MBRX Stock

According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.

Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.

To see Spark’s full report on MBRX stock, click here.

More about Moleculin Biotech

Moleculin Biotech, Inc. operates in the biotechnology industry, focusing on the development of oncology drug candidates. The company is primarily engaged in creating therapies for highly resistant tumors and other unmet medical needs.

Average Trading Volume: 4,315,301

Technical Sentiment Signal: Sell

Current Market Cap: $13.78M

For a thorough assessment of MBRX stock, go to TipRanks’ Stock Analysis page.